TUSTIN, Calif., Nov. 30, 2017 /PRNewswire/ -- Ricoh today announced that the RICOH MEG Measurement System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
RICOH MEG, Ricoh's magnetoencephalography system, is a noninvasive way to detect faint signals within the brain. It provides deeper measurement (hippocampus and hypothalamus), clearer signal using coaxial gradiometer sensors and greater patient comfort for better data acquisition.
"Ricoh is committed to helping advance research and treatment for neurological disorders, and MEG is another tool to help healthcare professionals and researchers measure brain activity," said Scott Abelson, Business Development Director, Medical Imaging, Ricoh USA, Inc.
Ricoh entered the medical device industry when it acquired a portion of a Yokogawa Electric business in 2016.
| About Ricoh |
Ricoh is empowering digital workplaces using innovative technologies and services enabling individuals to work smarter. For more than 80 years, Ricoh has been driving innovation and is a leading provider of document management solutions, IT services, commercial and industrial printing, digital cameras, and industrial systems.
Headquartered in Tokyo, Ricoh Group operates in approximately 200 countries and regions. In the financial year ended March 2017, Ricoh Group had worldwide sales of 2,028 billion yen (approx. 18.2 billion USD).
For further information, please visit www.ricoh.com
© 2017 Ricoh USA, Inc. All rights reserved. All referenced product names are
the trademarks of their respective companies.
Ricoh USA, Inc.
Breakaway Communications for Ricoh